The aim of this study was to measure the effect of moderate and intensive lipid-lowering treatment with rosuvastatin on the carotid intima-media thickness (CIMT) as a surrogate marker of cardiovascular risk.
The aim of this study was to measure the effect of moderate (5mg) and intensive (40mg) lipid-lowering treatment with rosuvastatin on the carotid intima-media thickness as a surrogate marker of cardiovascular risk and to obtain whether CIMT correlated with the plaque components in coronary arteries evaluated with Intravascular Ultrasound Virtual Histology (IVUS-VH).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
87
Rosuvastatin 5mg/day for one year
Rosuvastatin 40mg/day for one year
Department of Cardiology, Odense University Hospital
Odense, Fuenen, Denmark
change from baseline in mean CIMT
Average of the far wall of common and bulbus carotid artery
Time frame: baseline, 6month, 12 month
changes from baseline in max CIMT
Time frame: baseline, 6month, 12 month
change from baseline in mean common CIMT
Time frame: baaseline, 6month 12 month
change from baseline in max common CIMT
Time frame: baseline, 6month 12month
change from baseline in mean bulbus CIMT
Time frame: Baseline, 6month 12 month
change from baseline in max bulbus CIMT
Time frame: baseline, 6month 12month
change from baseline in lipid values
Time frame: baseline, 6month 12month
correlation between CIMT measurements and lipid values
Time frame: Baseline, 6month 12 month
correlation between CIMT measurements and plaque components evaluated by IVUS-VH
Time frame: Baseline, 6month 12month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.